Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Invested Capital (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Invested Capital for 6 consecutive years, with $956.8 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 6.45% to $956.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $956.8 million through Dec 2025, down 6.45% year-over-year, with the annual reading at $956.8 million for FY2025, 6.45% down from the prior year.
  • Invested Capital for Q4 2025 was $956.8 million at Janux Therapeutics, down from $976.6 million in the prior quarter.
  • The five-year high for Invested Capital was $1.0 billion in Q4 2024, with the low at -$16.8 million in Q1 2021.
  • Average Invested Capital over 5 years is $534.8 million, with a median of $371.5 million recorded in 2021.
  • The sharpest move saw Invested Capital skyrocketed 3358.49% in 2021, then dropped 12.9% in 2023.
  • Over 5 years, Invested Capital stood at $366.3 million in 2021, then decreased by 12.44% to $320.7 million in 2022, then grew by 7.36% to $344.3 million in 2023, then skyrocketed by 197.02% to $1.0 billion in 2024, then decreased by 6.45% to $956.8 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $956.8 million, $976.6 million, and $990.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.